Curaleaf Launches Share Repurchase Program

• On April 16, 2026, Curaleaf Holdings announced a Normal Course Issuer Bid (NCIB) to repurchase up to 34,380,831 subordinate voting shares.
• The program represents approximately 5% of outstanding shares with an estimated value of US$83 million based on the April 14 closing price.
• The buyback window runs from April 20, 2026, to April 19, 2027.
• Purchases are capped at 25% of average daily trading volume (approx. 210,139 shares/day).
• All repurchased shares will be canceled.
• The program commences after the release of Q1 2026 financial results.
• CEO Boris Jordan stated this reflects confidence in the strategy and strength of the company.

• Positive Sentiment: The announcement signals management confidence in cash flow generation and undervaluation of the stock at current levels ($3.60). It aligns with the "Return to Our Roots" strategy mentioned in February 2026 earnings, transitioning from stabilization to acceleration.
• Liquidity Concern: From a risk-averse perspective, committing $83 million to buybacks is aggressive given the cash position of only ~$101.6 million reported at the end of Q4 2025 (February 2026). While operating cash flow was strong ($152M in FY2025), reducing the cash buffer significantly increases vulnerability to operational shocks or regulatory changes.
• Capital Allocation: With debt carrying an 11.5% interest rate (from the Feb 2029 notes), using cash for buybacks rather than further deleveraging is a higher-risk capital allocation choice. It prioritizes shareholder return over balance sheet fortification in a volatile sector.
• Market Expectation: Given the strong Free Cash Flow ($89.3M) reported in February, some capital return was anticipated. This news confirms that expectation but does not fundamentally alter the investment thesis established by the refinancing and earnings reports earlier in 2026.

• Company: Curaleaf Holdings is a leading global cannabis company with operations in multiple US states (including Florida, Ohio, New York) and international markets (Germany, UK).
• Flagship Project: The core business is retail dispensary operations and branded product manufacturing. Key initiatives include the "Return to Our Roots" strategy focusing on high-margin core brands and operational efficiency.
• Development: In 2025-2026, the company has focused on margin expansion (gross margins ~50%), international growth (+63% YoY in FY2025), and balance sheet restructuring via debt refinancing.